AUSTIN, Texas–(BUSINESS WIRE)–Paradromics Inc., a neurotechnology company developing high-data-rate brain-computer interfaces to restore and enhance human capabilities, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol for its Connect-One Early Feasibility Study, removing the requirement that prospective participants live within a four-hour drive of a participating clinical site. Connexus® BCI is a fully implantable, wireless brain-comp

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.